About Congenital Myasthenic Syndromes
Congenital myasthenic syndromes (CMS) are a group of genetic disorders that affect neuromuscular transmission. This means that the communication between nerves and muscles is impaired, leading to muscle weakness.
CMS can occur at birth or during childhood, adolescence, or adulthood. The severity of muscle weakness can vary, with some individuals experiencing minor weakness and others being unable to walk. Facial muscles, including those controlling eyelids, eye movements, chewing, and swallowing, are commonly affected. However, any skeletal muscle can be involved. Infants with CMS may have feeding difficulties, and motor skill development may be delayed. Some individuals may also experience breathing problems or short pauses in breathing.
CMS is caused by mutations in genes involved in the organization, maintenance, function, or modification of the motor endplate. Early diagnosis and appropriate treatment are important for managing symptoms and improving quality of life.
Congenital myasthenic syndromes (CMS) are a group of rare inherited disorders that result in impaired neuromuscular transmission.
Risk factors:
- Genetic defects: CMS is primarily caused by germline pathogenic variants in genes expressed at the neuromuscular junction (NMJ). There are currently 35 known genes associated with CMS, including AGRN, CHAT, CHRND, LRP4, and many others.
It is important to note that CMS is a genetic disorder and not influenced by lifestyle choices or environmental factors. Therefore, there are no known modifiable risk factors for CMS.
If you have concerns about congenital myasthenic syndromes or its risk factors, it is best to consult with a healthcare professional who can provide you with individualized information and guidance.
The most common early symptoms of congenital myasthenic syndromes (CMS) include:
- Respiratory insufficiency with sudden apnea and cyanosis
- Feeding difficulties, poor suck, and cry
- Choking spells
- Eyelid ptosis (drooping eyelids)
- Facial, bulbar, and generalized weakness
As CMS progresses or becomes more severe, other common symptoms may occur, including:
- Abnormal muscle fatigability with difficulty in activities such as running or climbing stairs
- Delayed motor milestones (e.g., crawling or walking)
- Fluctuating eyelid ptosis
- Fixed or fluctuating weakness of the extraocular muscles (muscles that move the eyes)
- Episodes of breathing problems triggered by fevers or infection
- Short pauses in breathing (apnea) leading to a bluish appearance of the skin or lips (cyanosis)
It is important to note that the severity and course of CMS can vary among individuals, ranging from mild symptoms to progressive disabling weakness. Genetic testing is necessary to determine the specific subtype of CMS and guide treatment decisions. Consult with a healthcare professional for an accurate diagnosis and personalized management plan.
To diagnose congenital myasthenic syndromes, the following examinations, tests, and procedures are commonly performed:
- Medical history: Doctors review the patient’s symptoms, family history, and when muscle weakness began, often during infancy or childhood.
- Physical examination: They assess muscle strength, look for patterns of fatigue, and check if symptoms worsen with activity and improve with rest.
- Electromyography (EMG): This test measures the electrical activity in muscles to identify problems with nerve-to-muscle communication.
- Genetic testing: Genetic tests are performed to detect specific mutations associated with CMS and confirm the diagnosis.
- Blood tests: Bloodwork helps rule out other conditions, such as autoimmune myasthenia gravis, by checking for the absence of certain antibodies.
- Response to medication: Doctors may give drugs like acetylcholinesterase inhibitors to see if symptoms improve, which can indicate CMS.
It is important to consult with your healthcare provider about which specific examinations, tests, and procedures are appropriate for your individual situation.
The goals of treatment for congenital myasthenic syndromes (CMS) are to improve neuromuscular transmission, alleviate symptoms, and enhance quality of life.
Here are the different treatment options for CMS and how they work towards achieving these goals:
Medication:
- Acetylcholinesterase inhibitors: These medications increase the levels of acetylcholine, a neurotransmitter involved in neuromuscular transmission, by inhibiting its breakdown. This helps improve muscle strength and reduce fatigue.
Therapies:
- Physical therapy: Targeted exercises can help strengthen muscles and improve mobility.
- Respiratory therapy: Techniques such as breathing exercises and the use of respiratory devices can assist with breathing difficulties.
Therapeutic procedures:
- Plasmapheresis: This procedure involves removing antibodies from the blood, which can help reduce symptoms in some cases.
Health behavior changes:
- Avoiding triggers: Certain activities or stressors may worsen symptoms, so identifying and avoiding them can be beneficial.
- Adequate rest and pacing activities: Managing energy levels and avoiding overexertion can help minimize fatigue.
It is important to note that treatment approaches may vary depending on the specific genetic defect causing CMS. Therefore, it is crucial to consult with a healthcare professional for personalized advice.
Medication dosing may be affected by many factors. Check with your healthcare professional about dosing for your individual situation. Other side effects can occur. Check with your healthcare professional or read the information provided with your medication for additional side effect information.